In the pharmaceutical industry, there are a variety of medicinal products are manufactured which is needed to be dispensed. These products are packed in suitable containers and closures. It is demonstrated that the containers and closures should protect, preserve and safely deliver to patients. Containers are the storage device. They are use for drug product which placed and enclosed in it and direct contact with them. Pharmaceutical products will be packaged in a suitable type of container, which depends upon the types of products and packaging materials. An ideal packaging will protect the drug from the external environment (such as humidity, temperature, pressure) and prevent from exclude the O₂, CO₂, and volatile substances during transportation. It also gives protection against the physical, chemical, microbial, mechanical factors, and climate hazards. Closures are an important part of the packing system to enclose the mouth of containers and open or close quickly. Both containers and closures do not affect the therapeutic effect of the drug product. This review provides better information about containers, closures, packaging materials, etc.

Objective: To develop and validate a simple, efficient and cost-effective stability indicating RP-HPLC method for simultaneous estimation of Azilsartan and Chlorthalidone in Tablet dosage form. Methods: Phosphate buffer (ph4.0)-Methanol (60:40) used as mobile phase and stationary phase (250*4.6mm C18, Hypersil BDS) column, wavelength was selected 236 nm, Flow rate 1.0 ml/ min, injection volume 20 µl. Prepared Standard solution and sample solution at working concentration, used Mobile phase as diluent. Results: Elution order of both peaks, Chlorthalidone (Retention time 3.470 min.) eluted first and Azilsartan (Retention time 5.743 min.) second with good resolution and fulfil System suitability parameters. Precision results shows % Relative standard deviation of Azilsartan and Chlorthalidone 0.8 and 1.2 respectively. Linearity results of Azilsartan and Chlorthalidone found acceptable in range 20.0 µg/ml to 120 .0 µg/ml and 12.5 µg/ml to 75.0 µg/ml, respectively. Calibration curve shows good linearity and Correlation coefficient was 0.9999 of Azilsartan and Chlorthalidone. Recovery results of Azilsartan and Chlorthalidone from matrix of tablet formulation were 100.3% and 100.2%, respectively. Robustness and ruggedness results were found well within the acceptance limit. Conclusion: The results shows that the proposed simple, precise and accurate method can be successfully applied for simultaneous estimation of Azilsartan and Chlorthalidone in Tablet dosage form.

The main purpose of this study was to develop a topical drug delivery (Organogel) of Econazole to reduce the dose of the drug, to improve patient compliance, to avoid the side effects and increase local onset absorption. Econazole is an imidazole derivative antifungal to treat fungal and protozoal infections. Methods: Topical Organogel formulations of Econazole were prepared using span-60 with different penetration enhancer with their different concentrations. Six different formulations of econazole were prepared and evaluated with respect to their colour, Spreadability, viscosity parameter, determination of pH, formulation drug content, in vitro drug release studies, zeta potential studies, and stability studies. The Compatibility study was carried out by Fourier-transform infrared (FT-IR) spectral analysis.Results: FT-IR study revealed that there were no any significant interaction between the drug, excipients and polymers. All the designed formulations of Econazole show acceptable standard physical properties. The drug content and percentage yield were higher for F2 formulation among all formulation F2 shows better drug release. Stability study of the best formulation F2 (Coconut oil) shows that there was no difference in drug content and in vitro drug release studies. Conclusion: From the above observation results that this F2 formulation (Coconut oil) may be more encouraging topical substitute for the healing of fungal infections in the skin.

Tuberculosis (TB) is a communicable disorder from time to time because of the microorganism mycobacterium tuberculosis (MTB). Antitubercular agent acts as inhibiting the growth of Mycobacterium tuberculosis. Antitubercular agents specifically act with the aid of using inhibit the growth of microorganism with the aid of using cell wall synthesis inhibition. VXc-486 is a powerful antitubercular drug belonging with aminobenzimidazole category. The novel aminobenzimidazole, VXc-486, which targets gyrase B, potently inhibits a couple of drug-sensitive isolates and drug-resistant isolates of Mycobacterium tuberculosis. VXc-486 is crystalline and flakes in yellow colour having stable state. It is crystalline solid at room temperature that display physical feature of the drug. VXc-486 is water insoluble strong antitubercular drug that is the Aminobenzimidazole family drug.